Published: May 4, 2023 at 6:55 p.m. ET
Acelyrin said Thursday it has filed for an IPO.
The late-stage clinical biopharmaceutical company is offering 30 million common shares at a price of $18 each.
It applied to list its shares on the Nasdaq Global Select Market under the symbol SLRN.
The…
Acelyrin said Thursday it has filed for an IPO.
The late-stage clinical biopharmaceutical company is offering 30 million common shares at a price of $18 each.
It applied to list its shares on the Nasdaq Global Select Market under the symbol SLRN.
The deal is expected to close on May 9, it added.
Comments are closed.